MYC and hematologic disorder: To our knowledge, there are currently three other ongoing trials with a direct MYC inhibitor: one uses a MYC degrader called WBC100, in MYC-positive advanced solid tumours (NCT05100251), another is an epigenetic controller, OTX-2002, that downregulates MYC and is being tested in hepatocellular carcinoma (NCT05497453), while the third is with IDP-121, a stapled peptide MYC inhibitor being evaluated in patients with relapsed/refractory hematologic malignancies (NCT05908409).